HMGA2

Across TCGA pan-cancer cohorts, HMGA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HMGA2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher HMGA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HMGA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where HMGA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.489	0.901	<.001	22	view →
PDAC	DFS	Tertile	All	0.302	0.621	.002	18	view →
HNSC	OS	Median	All	0.484	1.000	.038	6	view →
CCRCC	OS	Quartile	III,IV	0.293	0.985	.010	2	view →
LSCC	DFS	Median	III,IV	0.829	0.492	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HMGA2–GBM (DFS)

Open the GBM breakdown →